+Follow
AlfredGJX
No personal profile
7
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
AlfredGJX
2021-03-18
Up
BRIEF-Ocugen Reports Full Year 2020 Financial Results
AlfredGJX
2021-03-18
Up up
AlfredGJX
2021-03-16
$Zomedica Pharmaceuticals Corp.(ZOM)$
Up up up
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3577928644113155","uuid":"3577928644113155","gmtCreate":1614835092890,"gmtModify":1615889525195,"name":"AlfredGJX","pinyin":"alfredgjx","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/c665ba6cb70a8ee99cf786716110d953","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":7,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":327183183,"gmtCreate":1616069833142,"gmtModify":1704790483214,"author":{"id":"3577928644113155","authorId":"3577928644113155","name":"AlfredGJX","avatar":"https://static.tigerbbs.com/c665ba6cb70a8ee99cf786716110d953","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577928644113155","authorIdStr":"3577928644113155"},"themes":[],"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327183183","repostId":"2120215281","repostType":2,"repost":{"id":"2120215281","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1616067189,"share":"https://ttm.financial/m/news/2120215281?lang=&edition=fundamental","pubTime":"2021-03-18 19:33","market":"us","language":"en","title":"BRIEF-Ocugen Reports Full Year 2020 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2120215281","media":"Reuters","summary":"March 18 (Reuters) - Ocugen Inc : * OCUGEN INC - CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TOT","content":"<html><body><p>March 18 (Reuters) - Ocugen Inc :</p><p> * OCUGEN INC - CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TOTALED $24.2 MILLION AS OF DECEMBER 31, 2020, COMPARED TO $7.6 MILLION AS OF DECEMBER 31, 2019</p><p> * OCUGEN - PREPARING TO FILE INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE FIRST TWO CLINICAL TRIALS FOR OCU400 IN SECOND HALF OF THIS YEAR</p><p>Source text for Eikon: Further company coverage: </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ocugen Reports Full Year 2020 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ocugen Reports Full Year 2020 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-18 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>March 18 (Reuters) - Ocugen Inc :</p><p> * OCUGEN INC - CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TOTALED $24.2 MILLION AS OF DECEMBER 31, 2020, COMPARED TO $7.6 MILLION AS OF DECEMBER 31, 2019</p><p> * OCUGEN - PREPARING TO FILE INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE FIRST TWO CLINICAL TRIALS FOR OCU400 IN SECOND HALF OF THIS YEAR</p><p>Source text for Eikon: Further company coverage: </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2120215281","content_text":"March 18 (Reuters) - Ocugen Inc : * OCUGEN INC - CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TOTALED $24.2 MILLION AS OF DECEMBER 31, 2020, COMPARED TO $7.6 MILLION AS OF DECEMBER 31, 2019 * OCUGEN - PREPARING TO FILE INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE FIRST TWO CLINICAL TRIALS FOR OCU400 IN SECOND HALF OF THIS YEARSource text for Eikon: Further company coverage: ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":18,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":327189418,"gmtCreate":1616069789234,"gmtModify":1704790482890,"author":{"id":"3577928644113155","authorId":"3577928644113155","name":"AlfredGJX","avatar":"https://static.tigerbbs.com/c665ba6cb70a8ee99cf786716110d953","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577928644113155","authorIdStr":"3577928644113155"},"themes":[],"htmlText":"Up up","listText":"Up up","text":"Up up","images":[{"img":"https://static.tigerbbs.com/3f8f2c03894f47111506fbb31c7973c6","width":"1125","height":"3177"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327189418","isVote":1,"tweetType":1,"viewCount":24,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":325820952,"gmtCreate":1615887307176,"gmtModify":1704787945559,"author":{"id":"3577928644113155","authorId":"3577928644113155","name":"AlfredGJX","avatar":"https://static.tigerbbs.com/c665ba6cb70a8ee99cf786716110d953","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577928644113155","authorIdStr":"3577928644113155"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>Up up up","listText":"<a href=\"https://laohu8.com/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>Up up up","text":"$Zomedica Pharmaceuticals Corp.(ZOM)$Up up up","images":[{"img":"https://static.tigerbbs.com/ef81f451ea7646f22f1196a25deb030f","width":"1284","height":"2223"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/325820952","isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":327183183,"gmtCreate":1616069833142,"gmtModify":1704790483214,"author":{"id":"3577928644113155","authorId":"3577928644113155","name":"AlfredGJX","avatar":"https://static.tigerbbs.com/c665ba6cb70a8ee99cf786716110d953","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577928644113155","authorIdStr":"3577928644113155"},"themes":[],"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327183183","repostId":"2120215281","repostType":2,"repost":{"id":"2120215281","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1616067189,"share":"https://ttm.financial/m/news/2120215281?lang=&edition=fundamental","pubTime":"2021-03-18 19:33","market":"us","language":"en","title":"BRIEF-Ocugen Reports Full Year 2020 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2120215281","media":"Reuters","summary":"March 18 (Reuters) - Ocugen Inc : * OCUGEN INC - CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TOT","content":"<html><body><p>March 18 (Reuters) - Ocugen Inc :</p><p> * OCUGEN INC - CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TOTALED $24.2 MILLION AS OF DECEMBER 31, 2020, COMPARED TO $7.6 MILLION AS OF DECEMBER 31, 2019</p><p> * OCUGEN - PREPARING TO FILE INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE FIRST TWO CLINICAL TRIALS FOR OCU400 IN SECOND HALF OF THIS YEAR</p><p>Source text for Eikon: Further company coverage: </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ocugen Reports Full Year 2020 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ocugen Reports Full Year 2020 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-18 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>March 18 (Reuters) - Ocugen Inc :</p><p> * OCUGEN INC - CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TOTALED $24.2 MILLION AS OF DECEMBER 31, 2020, COMPARED TO $7.6 MILLION AS OF DECEMBER 31, 2019</p><p> * OCUGEN - PREPARING TO FILE INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE FIRST TWO CLINICAL TRIALS FOR OCU400 IN SECOND HALF OF THIS YEAR</p><p>Source text for Eikon: Further company coverage: </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2120215281","content_text":"March 18 (Reuters) - Ocugen Inc : * OCUGEN INC - CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TOTALED $24.2 MILLION AS OF DECEMBER 31, 2020, COMPARED TO $7.6 MILLION AS OF DECEMBER 31, 2019 * OCUGEN - PREPARING TO FILE INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE FIRST TWO CLINICAL TRIALS FOR OCU400 IN SECOND HALF OF THIS YEARSource text for Eikon: Further company coverage: ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":18,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":327189418,"gmtCreate":1616069789234,"gmtModify":1704790482890,"author":{"id":"3577928644113155","authorId":"3577928644113155","name":"AlfredGJX","avatar":"https://static.tigerbbs.com/c665ba6cb70a8ee99cf786716110d953","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577928644113155","authorIdStr":"3577928644113155"},"themes":[],"htmlText":"Up up","listText":"Up up","text":"Up up","images":[{"img":"https://static.tigerbbs.com/3f8f2c03894f47111506fbb31c7973c6","width":"1125","height":"3177"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327189418","isVote":1,"tweetType":1,"viewCount":24,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":325820952,"gmtCreate":1615887307176,"gmtModify":1704787945559,"author":{"id":"3577928644113155","authorId":"3577928644113155","name":"AlfredGJX","avatar":"https://static.tigerbbs.com/c665ba6cb70a8ee99cf786716110d953","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577928644113155","authorIdStr":"3577928644113155"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>Up up up","listText":"<a href=\"https://laohu8.com/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>Up up up","text":"$Zomedica Pharmaceuticals Corp.(ZOM)$Up up up","images":[{"img":"https://static.tigerbbs.com/ef81f451ea7646f22f1196a25deb030f","width":"1284","height":"2223"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/325820952","isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}
